



## Mycamine<sup>®</sup> (micafungin) – First-time generic

- On April 22, 2020, Fresenius Kabi launched an AP-rated generic version of Astellas' Mycamine (micafungin) injection.
- Mycamine is indicated for:
  - Treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses in adult and pediatric patients 4 months of age and older
  - Treatment of candidemia, acute disseminated candidiasis, *Candida* peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age
  - Treatment of esophageal candidiasis in adult and pediatric patients 4 months of age and older
  - Prophylaxis of *Candida* infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.